NCT06270511View on ClinicalTrials.gov

A Study to Investigate Different Formulations of S-337395 in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 13, 2024

Primary Completion Date

May 30, 2024

Study Completion Date

June 19, 2024

Conditions
Healthy Volunteers
Interventions
DRUG

S-337395

Administered as an oral suspension.

DRUG

Placebo

Administered as an oral suspension.

Trial Locations (1)

66219

ICON Lenexa, Lenexa

Sponsors

Lead Sponsor

Shionogi
All Listed Sponsors
lead

Shionogi

INDUSTRY